Fast Market Research announces the availability of the new Global Markets Direct report, "HIV / AIDS - Pipeline Review, H2 2015", on their comprehensive research portal
Boston, MA -- (SBWIRE) -- 02/18/2016 -- Global Markets Direct's, 'HIV / AIDS - Pipeline Review, H2 2015', provides an overview of the HIV / AIDS's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for HIV / AIDS, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV / AIDS and special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Get More Details on this Report and a Full Table of Contents at HIV / AIDS - Pipeline Review, H2 2015
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
-The report provides a snapshot of the global therapeutic landscape of HIV / AIDS
-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in the therapeutics development for HIV / AIDS and enlists all their major and minor projects
-The report summarizes all the dormant and discontinued pipeline projects
-A review of the HIV / AIDS products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-A detailed assessment of monotherapy and combination therapy pipeline projects
-Coverage of the HIV / AIDS pipeline on the basis of target, MoA, route of administration and molecule type
-Latest news and deals relating related to pipeline products
Reasons to Get this Report
-Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Develop strategic initiatives by understanding the focus areas of leading companies
-Identify and understand important and diverse types of therapeutics under development for HIV / AIDS
-Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
-Devise corrective measures for pipeline projects by understanding HIV / AIDS pipeline depth and focus of Indication therapeutics
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned in this Report: Abivax S.A., Adaptimmune Limited, AiCuris GmbH & Co. KG, Akshaya Bio Inc., Altor BioScience Corporation, AltraVax Inc., Amarna Therapeutics B.V., American Gene Technologies International Inc., Amplyx Pharmaceuticals, Inc., Antigen Express, Inc., Aphios Corporation, Apotex, Inc., Argos Therapeutics, Inc., Arno Therapeutics, Inc., Avexa Limited, BCI Pharma, Beth Israel Deaconess Medical Center, Inc., BioClonetics Immunotherapeutics, Inc., Bionor Pharma ASA, Biosantech SA, BioSource Pharm, Inc., Biotron Limited, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, C4X Discovery Limited, Calimmune, Inc., Celldex Therapeutics, Inc., Chipscreen Biosciences Ltd, Cocrystal Pharma, Inc., CompleGen, Inc., Critical Outcome Technologies Inc., CureVac GmbH, Cytodyn Inc., DNAVEC Corporation, Dong-A ST Co., Ltd., Enzo Biochem, Inc., EpiVax, Inc., Etubics Corporation, Evofem, Inc., FIT Biotech Oy, Formune S.L., Fountain Biopharma Inc., Frontier Biotechnologies Co., Ltd, GeneCure LLC, Genetic Immunity, Inc, Genticel S.A., GeoVax Labs, Inc., Gilead Sciences, Inc., GlaxoSmithKline Plc, Globeimmune, Inc., H-Phar S.A., Hadasit Medical Research Services & Development Ltd, Heat Biologics, Inc., Heptares Therapeutics Limited, Humabs BioMed SA, iCo Therapeutics Inc., Immune Response BioPharma, Inc., Immunocore Limited, Immunomic Therapeutics, Inc., Immuron Limited, ImQuest Life Sciences, InnaVirVax SA, Inovio Pharmaceuticals, Inc., Japan Tobacco Inc., Johnson & Johnson, KAEL-GemVax Co., Ltd., Karyopharm Therapeutics, Inc., Kineta, Inc., Laboratorios Del Dr. Esteve S.A., Longevity Biotech, Inc, MacroGenics, Inc., Medestea Research & Production S.p.A., Medivir AB, Merck & Co., Inc., Mologen AG, Mymetics Corporation, Myrexis, Inc., NanoBio Corporation, NanoViricides, Inc., Navigen Pharmaceuticals, Inc., NeED Pharma s.r.l., Nektar Therapeutics, New World Laboratories, Inc., Novartis AG, Omeros Corporation, Oncolys BioPharma Inc., OncoNOx ApS, Oncovir, Inc., Orbis Biosciences, Inc., Osel Inc., OyaGen Inc., PaxVax, Inc., Pepscan Therapeutics, Peregrine Pharmaceuticals, Inc., Pfizer Inc., Pharis Biotec GmbH, Pharmsynthez, Phoenix Biotechnology, Inc., Polymun Scientific Immunbiologische Forschung GmbH, Presidio Pharmaceuticals, Inc., Profectus BioSciences, Inc., RAPID Pharmaceuticals AG, ReceptoPharm, Inc., Rodos BioTarget GmbH, Rottapharm SpA, Sangamo BioSciences, Inc., Sanofi, Sanofi Pasteur SA, Savoy Pharmaceuticals, Inc., SEEK Group, Sequoia Pharmaceuticals, Inc., Serometrix, LLC, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., SKAU Vaccines ApS, Spider Biotech, Starpharma Holdings Limited, Susavion Biosciences, Inc., Taiga Biotechnologies, Inc., TaiMed Biologics Inc., Takara Bio Inc., TAmiRNA GmbH, TechnoVax, Inc., TetraLogic Pharmaceuticals, Teva Pharmaceutical Industries Limited, TGV-Laboratories, Theraclone Sciences, Inc., Theravectys SA, Tobira Therapeutics, Inc., Transgene Biotek Limited, TVAX Biomedical, Inc., United Biomedical, Inc., United Therapeutics Corporation, Vaccibody AS, VG Life Sciences, Inc., Vichem Chemie Research Ltd., ViiV Healthcare Limited, Viriom Ltd., ViroLogik GmbH, ViroXis Corporation
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Drug Pipeline research reports at Fast Market Research
You may also be interested in these related reports:
-HIV-1 Infection - Pipeline Review, H2 2015
-AIDS - Related Kaposi's Sarcoma - Pipeline Review, H2 2015
-Herpes Simplex Infections - Pipeline Review, H2 2015
-Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015
-H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2015